非小细胞肺癌与表皮生长因子受体 (EGFR) 常见突变:新策略
Brigida Stanzione1, Alessandro Del Conte1, Elisa Bertoli1
1Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Cancers
|May 14, 2025
概括
表皮生长因子受体 (EGFR) 突变驱动非小细胞肺癌 (NSCLC). 需要新的策略来克服对向疗法 (如奥西默提尼布) 的耐药性,并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素,特别是在亚洲人群中.
- 氨酸激酶抑制剂 (TKIs) 已经改变了NSCLC的治疗方法,但疾病的进展仍然是一个重大挑战.
研究的目的:
- 审查目前改善EGFR突变NSCLC患者预后的策略.
- 解决对增强的第一线和有效的第二线治疗的未满足需求.
主要方法:
- 对EGFR突变NSCLC的治疗策略的文献综述.
- 分析NSCLC管理中的治疗进展和未满足需求.
主要成果:
- 第三代TKIOsimertinib显示出有效性,但在大多数患者中随之而来的是疾病进展.
- 确定新的治疗途径,以增强现有治疗方法,并建立强大的二线选择.
结论:
- 改善EGFR突变NSCLC的预后需要超越当前技术知识的创新方法.
- 对组合疗法和新药的进一步研究对于克服治疗耐药性和延长生存时间至关重要.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.5K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
